The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials.Adoptive cell therapy (ACT), such as chimeric antigen receptor (CAR) T-cell therapy, has demonstrated promising therapeutic effects with potentially non-monotonic dose-response curves. 
Ji3+3
The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials.Adoptive cell therapy (ACT), such as chimeric antigen receptor (CAR) T-cell therapy, has demonstrated promising therapeutic effects with potentially non-monotonic dose-response curves. 
Ji3+3